- Home
- SLXN vs SQFT Comparison
SLXN vs SQFT Comparison
Compare SLXN & SQFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- SQFT
- Stock Information
- Founded
- SLXN 2008
- SQFT 1999
- Country
- SLXN Israel
- SQFT United States
- Employees
- SLXN N/A
- SQFT N/A
- Industry
- SLXN
- SQFT Real Estate Investment Trusts
- Sector
- SLXN
- SQFT Real Estate
- Exchange
- SLXN NYSE
- SQFT Nasdaq
- Market Cap
- SLXN 6.9M
- SQFT 8.1M
- IPO Year
- SLXN N/A
- SQFT 2020
- Fundamental
- Price
- SLXN $0.95
- SQFT $5.15
- Analyst Decision
- SLXN Strong Buy
- SQFT
- Analyst Count
- SLXN 1
- SQFT 0
- Target Price
- SLXN $5.00
- SQFT N/A
- AVG Volume (30 Days)
- SLXN 1.2M
- SQFT 3.6K
- Earning Date
- SLXN 05-13-2025
- SQFT 06-17-2025
- Dividend Yield
- SLXN N/A
- SQFT N/A
- EPS Growth
- SLXN N/A
- SQFT N/A
- EPS
- SLXN N/A
- SQFT N/A
- Revenue
- SLXN N/A
- SQFT $18,260,398.00
- Revenue This Year
- SLXN N/A
- SQFT $23.63
- Revenue Next Year
- SLXN N/A
- SQFT N/A
- P/E Ratio
- SLXN N/A
- SQFT N/A
- Revenue Growth
- SLXN N/A
- SQFT N/A
- 52 Week Low
- SLXN $0.58
- SQFT $4.70
- 52 Week High
- SLXN $41.85
- SQFT $8.77
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- SQFT 28.90
- Support Level
- SLXN N/A
- SQFT $5.00
- Resistance Level
- SLXN N/A
- SQFT $5.95
- Average True Range (ATR)
- SLXN 0.00
- SQFT 0.27
- MACD
- SLXN 0.00
- SQFT -0.10
- Stochastic Oscillator
- SLXN 0.00
- SQFT 11.00
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.